Serum sclerostin and Dickkopf-related protein 1 levels of axial spondyloa rthritis can be raised by selective cyclo-oxygenase 2 inhibitor
10.3760/cma.j.issn.1007-7480.2018.03.004
- VernacularTitle:选择性环加氧酶2抑制剂对中轴型脊柱关节炎血清DKK1和硬化蛋白水平的影响
- Author:
Guanmin GAO
1
;
Zhixun LI
;
Xiaolong ZHENG
;
Leilei ZHANG
;
Guoliang WANG
;
Jungen TANG
;
Yanke GUO
;
Shengyun LIU
;
Cuiping REN
Author Information
1. 450052,郑州大学第一附属医院河南省高等学校临床医学重点学科开放实验室风湿免疫科
- Keywords:
Osteoarthritis,spine;
Cyclooxygenase 2 inhibitors;
Dickkopf-related protein 1;
Sclerostin
- From:
Chinese Journal of Rheumatology
2018;22(3):158-164
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the serum levels of dickkopf-related protein 1 (DKK1) and sclerostin (SOST) in patients with axial spondyloarthritis treated with selective cyclo-oxygenase 2 inhibitor and its relation to clinical efficacy.Methods A randomized double-blind controlled trial with axial spondyloarthritis (ax-SpA) was carried out in our hospital.The data from patients in a single center was collected and analyzed.Serum DKK1 and SOST levels were measured by enzyme-linked immuno sorbent assay (ELISA)method before and after 12 weeks treatment,then correlation analysis were conducted for DKK1 and SOST levels with erythrocyte sedimentation rate (ESR),C reactive protein (CRP),Bath ankylosing spondylitis disease activity index (BASDAI),Bath ankylosing spondylitis functional index (BASFI) and SPARCC of the sacroiliac joint inflammation score.Chi-square tests were used for analyzing of categorical data.Fisher exact tests were performed when the expected frequencies were less than 5.Two independent samples t-test was used to compare the difference between groups.Single sample t-test was used to ompare the differences between data before and after treatment.Pearson or Spearman correlation was used for correlation analysis.Results After 12 weeks of treatment,a total of 116 patients completed the follow-up,including 57 cases of imrecoxib group and 59 cases of the celecoxib group.There were no statistically significant difference between the two groups (P＞0.05).The level of serum DKK1 was significantly increased after treatment [(393±137) pg/ml,vs (542±274)pg/ml,P＜0.05].The serum level of SOST increased significantly [(39±19) pg/ml vs (57±36) pg/ml,t=5.814,P＞0.05],too.The difference between the two groups was not statistically significant (P＞0.05).Spearman correlation analysis showed that serum DKK1 was positively correlated with serum SOST (r=0.226,P=0.015).A significantcorrelation was found between SOST level and ESR,CRP,finger to floor distance,left and fight lumbar side flexion and Schober's test (ESR:r=-0.379,P＜0.01;r=-0.309,P=0.001;r=-0.225,P=0.015;r=0.185,P=0.047;r=0.247,P=0.008;r=0.214,P=0.021).Conclusion Imrecoxib and celecoxib have similar efficacy on relieving the signs and symptoms of patients with ax-SpA.Short-term application of selective COX-2 inhibitors can increase DKK1 and SOST and possibly delay radiographic progression.
